These strategies aiming to use CAR-T cells modified to resist the immunosuppression induced by the TME derived TGF-β are currently undergoing clinical trials in hematological cancers and solid tumors such as prostate cancer (NCT03089203, NCT04227275). Here, TGFB1 is linked to prostate cancer.